Time to Submit Comment
Letters to CMS and Congress!
CMS has issued two proposed rules that will set 2027 Medicare payment for interventional pain management: the CY 2027 Physician Fee Schedule and the CY 2027 OPPS/ASC Payment System. ASIPP is commenting on both. We ask that every State Society also file its own separate comment letter. Letters from societies across the country show CMS the nationwide impact on physicians, independent practices, ASCs, and Medicare patients.
Here are links to two sample letters:
| | Comment Deadline is August 31, 2026 | | Comment Deadline is September 14, 2026 | |
INSTRUCTIONS FOR OPENING LETTERS
When you click on the sample letter links, the letters will automatically download to your Downloads folder.
Please use them as a starting point, not as a form.
Identical letters carry little weight with CMS. We ask you to rewrite using your own letterhead, change the wording and order, add state-specific examples, and keep ASIPP’s key issues and requests.
Please also write to Congress. Send letters to both of your U.S. Senators and to one member of your U.S. House delegation, asking for an annual inflation update to Medicare physician payment and relief from budget neutrality.
Click here for Senator contact information.
Click here for Representative contact information.
The OPPS/ASC deadline is less than two weeks away. Please act now.
Thank you for your continued support and advocacy on behalf of ASIPP and Medicare beneficiaries.
| | |
This nationwide audit was conducted to determine whether Medicare paid physicians for sacroiliac joint injections in accordance with Medicare requirements and guidance. OIG found that of the 100 sampled sessions, 72 did not comply with Medicare requirements.
In addition, of the 100 sampled sessions, physicians’ billing for 25 sessions did not meet Medicare guidance. Based on OIG sample results, it is estimated that Medicare improperly paid $15.2 million for 134,526 of 186,842 total sessions from October 1, 2023, through September 30, 2024.
Why OIG Did This Audit
- Sacroiliac joint injections (a type of spinal pain management service) are covered under Medicare Part B when medically reasonable and necessary.
- In two prior audits of facet-joint interventions (another type of spinal pain management service), OIG found that Medicare paid for more than 50 percent of the sampled services that did not comply with one or more Medicare requirements.
- Because OIG identified a high risk of noncompliance with facet-joint interventions, they conducted this nationwide audit to determine whether Medicare paid physicians for sacroiliac joint injections in accordance with Medicare requirements and guidance.
Click here to read the full report.
| |
Ready to build your practical skills?
Join ASIPP in Memphis on August 28–29 for hands-on workshops in Ultrasound for Regenerative Medicine, Regenerative Medicine, and Interventional Techniques in IPM.
Also offering a $200 PNS workshop and a $100 introduction to the VIA Disc NP procedure.
Space is limited for these workshops. Early registration is encouraged.
Click here to learn more.
| |
Thank you to everyone who joined our highly
successful Peripheral Nerve Stimulation webinar!
We invite you to continue your educational experience
by joining us at the $200 PNS Hands-On Workshop.
| | | |
FRIDAY, AUGUST 28
Ultrasound for Regenerative Medicine Hands-On Workshop
Earn 8 CMEs while gaining practical ultrasound experience focused on regenerative medicine applications.
| | | |
SATURDAY, AUGUST 29
Regenerative Medicine Hands-On Cadaver Workshop
(Basic, Intermediate, & Advanced)
Earn 8 CMEs in this cadaver workshop with hands-on instruction covering regenerative medicine techniques across varying experience levels.
| | | |
SATURDAY, AUGUST 29
Interventional Techniques in IPM Hands-On Cadaver Workshop
(Basic, Intermediate & PNS)
Earn 8 CMEs in this workshop focused on interventional pain management techniques and peripheral nerve stimulation applications.
| | |
CMS has released the CY 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P). The overall picture is unfavorable: CMS estimates a combined -2% impact on interventional pain management, with additional proposals affecting E/M billing, MIPS, and imaging/laboratory payment. Two documents are attached — the proposed rule and ASIPP’s code-by-code payment comparison for 2027 vs. 2026. Key points below.
Conversion Factor: Proposed Cut
With the one-year 2.5% statutory increase for 2026 expiring, CMS proposes:
-
Qualifying APM participants: $33.17, down from $33.57 (-1.19%)
-
All other clinicians (non-QP): $32.84, down from $33.40 (-1.68%)
These figures reflect a +0.53% budget-neutrality adjustment and statutory updates of +0.75% (QP) and +0.25% (non-QP). They do not include the 2% sequester or potential 4% PAYGO cuts.
IPM Codes: Widespread Reductions vs. 2026
Most interventional pain codes are cut 1–6% in the office setting and 1-4% in Facility:
| |
- Trigeminal nerve injection (64400): -19.9%; greater occipital nerve (64405): -16.6%
- Percutaneous SI joint fusion (27279, facility): -14.9%
- Kyphoplasty (22513–22515): -6.0% to -6.1%
- Spinal cord stimulator trial (63650): -5.9%; percutaneous
- PNS (64555): -6.3%
A handful of codes see small increases (e.g., blood patch 62273, several peripheral nerve blocks). The attached table shows every IPM code.
E/M Services: Major Change to Modifier -25
CMS proposes that when a separately identifiable office E/M visit is billed with modifier -25 on the same day as a 0-, 10-, or 90-day global procedure, only the highest-paid service is paid at 100% — all others, including the E/M visit, are cut 50%. This directly targets the common office-based scenario of a same-day evaluation and injection. CMS also proposes replacing add-on code G2211 with modifier MOD1, valued at 16% of the base E/M code (32% for ACO participants via MOD2). E/M payment rates themselves decline modestly (see attached table).
MIPS / Quality Payment Program
- Traditional MIPS would sunset with the CY 2029 performance period (2031 payment year), making MIPS Value Pathways (MVPs) the sole reporting option; three new MVPs are proposed.
- The quality measure inventory would be set at 180 measures (20 removals, 10 additions), with a new MIPS core measure reporting requirement replacing the outcome/high-priority measure requirement (small practices exempt).
- The performance threshold remains 75 points. Separately, the rule proposes refinements to the Ambulatory Specialty Model (ASM), the mandatory model whose low back pain cohort includes interventional pain physicians.
RFI: Duplicate Laboratory Testing, Imaging, and Interoperability
CMS is seeking input on mechanisms to address duplicate laboratory and imaging tests, including MAC edits resulting in non-payment or reduced payment, recoupment of payments, frequency limitations, and revised billing instructions, along with improved result sharing and interoperability. These policies could significantly affect pain practices that rely on imaging and drug testing. ASIPP will submit detailed comments — please send us your input.
Act Now
Comments are due September 14, 2026 (file code CMS-1848-P). Please review the attached documents and send your feedback to asipp@asipp.org so we can represent you forcefully. ASIPP will fight these cuts, as we always have — but your voice makes the difference.
View the CY 2027 PFS Proposed Rule Fact Sheet
View the ASIPP 2027 vs. 2026 Proposed Payment Rate Comparison for IPM Codes
| | SAVE THE DATE - APRIL 15-17, 2027 | | |
Save the date for the American Society of Interventional Pain Physicians' 29th Annual Meeting, April 15 - 17, 2027, in Orlando, Florida.
This flagship educational event will bring together physicians, researchers, and healthcare professionals from across the country for three days of cutting-edge education, collaboration, and professional networking.
Attendees can look forward to our most comprehensive Annual Meeting yet, featuring new educational topics, expanded faculty participation, and innovative program enhancements designed to keep you at the forefront of interventional pain management.
Mark your calendar now and plan to join us in Orlando as we continue advancing excellence in interventional pain management. Additional program details and faculty announcements will be released soon.
Register by October 1, 2026, to receive a 10% Early Bird Discount.
| |
Half of procedures occurred in settings not supported by guidelines
| | |
ASIPP is proud to launch our Resident and Fellow Mentorship Program. This initiative is designed to connect trainees with experienced pain physicians to foster professional growth, provide guidance, and strengthen the future of our specialty.
Each mentor would be paired with one to two trainees, but can take more if interested. Trainees will be responsible for initiating introductions and arranging at least one to two video calls per year. These sessions will provide opportunities for mentees to seek advice on clinical decision-making, career planning, research opportunities, and professional development.
We believe that your experience, expertise, and insight can have a lasting impact on the next generation of pain physicians. By volunteering as a mentor, you will play a critical role in shaping the future of our field and ensuring that ASIPP continues to cultivate excellence in interventional pain medicine.
If you are interested in serving as a mentor, please confirm your participation by filling out the appropriate form below.
| | |
A key federal advisory committee hasn't weighed in
By this time of year, both the FDA and CDC normally have weighed in on fall respiratory virus vaccine recommendations. But given ongoing controversies over vaccination spurred by the Trump administration, a wrench has once again been thrown into the gears of that process.
The FDA has done its part, making recommendations about vaccine composition for influenza vaccines in March, followed by recommendations for COVID shots in May. But the CDC's Advisory Committee on Immunization Practices (ACIP) hasn't done its part as it hasn't held its March or June meetings this year.
Typically, after the FDA meets, ACIP "then meets and makes recommendations about how to use those vaccines," David Freedman, MD, professor emeritus of infectious diseases at the University of Alabama at Birmingham and spokesperson for the Infectious Diseases Society of America (IDSA), told Medpage Today.
Click here to read the full article.
| |
ASIPP is pleased to announce the launch of the Regenerative and Longevity Medicine Section!
This section reflects the growing importance of regenerative and longevity medicine—fields dedicated to restoring health, enhancing vitality, and extending the healthy years of life. From stem cell therapies and tissue engineering to gene therapy and orthobiologics, these disciplines are transforming the way we approach pain management and age-related decline.
Section membership offers:
- Access to ASIPP’s physician database and future data registry
- Opportunities for certification and continuing education
- Section-exclusive resources and updates
No additional cost for ASIPP members!
| |
Several members seem to have "disqualifying financial interests," consumer group says
A consumer watchdog group is demanding that the HHS Office of Inspector General (OIG) look into potential conflicts of interest among members of an FDA advisory committee that recommended that six peptides be added to the list of substances that can be compounded, despite a lack of evidence of their efficacy.
"Several members of the 2026 Pharmacy Compounding Advisory Committee (PCAC) appear to have had disqualifying financial interests in the pharmaceutical and peptide industries at the time of the July 23-24, 2026, meeting related to peptide therapies," Kedric Payne, vice president and general counsel at the Campaign Legal Center, and Margaret Dylus-Yukins, the group's senior legal counsel for ethics, wrote last week in a letter to HHS Inspector General T. March Bell.
"Despite publicly available information to the contrary, the FDA Office of Ethics and Integrity (OEI) found that none of the 2026 PCAC members had any conflicts of interest and allowed them to participate in the meeting without ethics waivers," they added. "The Campaign Legal Center asks that HHS OIG investigate FDA OEI's ethics decisions and determine if the 2026 PCAC members violated criminal ethics laws by participating in the meeting without waivers in place."
Click here to read the full article.
| | |
Apply now for one of the following 2026 dates:
October 24, November 14,
& December 12
Four (4) hour virtual exam
- ABIPP Path – Combined CCPM/ CSM Exam
For those with subspecialty in Pain Medicine
Two (2) hour virtual exam
- ABIPP Competency Exam in IPM
For those without primary board certification
Two (2) hour virtual exam
- ABIPP Competency Exam in Regenerative Medicine
Two (2) hour virtual exam
- Controlled Substance Management Competency Exam
Two (2) hour virtual exam
- Documentation, Coding, Compliance, Practice Management Competency Exam
Two (2) hour virtual exam
| | |
Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.
Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.
Interested in becoming a member of the PMCR Editorial Board?
Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.
For more information or to submit your articles, click here.
| | |
We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.
The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.
The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.
We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.
| | | | |